Roche seals two deals in one weekend

Share this article:

Roche closed two deals over one weekend: buying a drug from Spain's Oryzon Genomics and scooping up the Massachusetts company IQuum.

As reported by Bloomberg, the $21-million Oryzon deal is for an experimental drug that prevents cancers from growing and gives Roche “its first drug in human testing in the field of epigenetics,” a strategy in which doctors try to alter gene expression without DNA modification. The treatment is for acute myeloid leukemia. Bloomberg says Oryzon could garner an additional $500 million in milestone payments.

Roche's IQuum deal brings the private company's Laboratory-in-a-Tube system (known as Liat) into Roche's portfolio in exchange for $275 million, with a possible $175 million in additional payments. Roche said in a statement that IQuum will become part of Roche's Diagnostics division. The system “allows healthcare professionals to perform rapid molecular diagnostic testing in a point of care setting, closer to patients and with minimal training,” the company said.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.